WASHINGTON — Scott Gottlieb, commissioner of the Food and Drug Administration, announced new steps the agency would take to promote the use and development of medication-assisted treatment for substance use disorder at a House hearing on Wednesday.
Gottlieb also rapped the insurance industry for what he called “often inadequate” coverage of existing therapies that combine counseling and medication-assisted treatment.
“To tackle the treatment gap, FDA is planning to convene experts and stakeholders to discuss the evidence of treatment benefits at the population level — such as studies that show community-wide reductions in overdose following expansion of access to therapy,” Gottlieb said.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect